Evidence map›Paper›PMID 39062549›Full record

ReviewBiomolecules2024

Interplay between Comorbidities and Long COVID: Challenges and Multidisciplinary Approaches.

Rasha Ashmawy, Esraa Abdellatif Hammouda, Yousra A El-Maradny, Iman Aboelsaad, Mai Hussein, Vladimir N Uversky, Elrashdy M Redwan

Abstract readReview
In one paragraph

Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rasha AshmawyClinical Research Administration, Directorate of Health Affairs, Ministry of Health and Population, Alexandria 21554, Egypt.ORCID 0000-0003-2689-5968
Esraa Abdellatif HammoudaBiomedical Informatics and Medical Statistics, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.ORCID 0000-0003-3269-6623
Yousra A El-MaradnyPharmaceutical and Fermentation Industries Development Center, City of Scientific Research and Technological Applications (SRTA-City), New Borg EL-Arab 21934, Alexandria, Egypt.ORCID 0000-0001-9501-8059
Iman AboelsaadClinical Research Administration, Directorate of Health Affairs, Ministry of Health and Population, Alexandria 21554, Egypt.ORCID 0000-0002-9412-1668
Mai HusseinClinical Research Administration, Directorate of Health Affairs, Ministry of Health and Population, Alexandria 21554, Egypt.
Vladimir N UverskyDepartment of Molecular Medicine and USF Health Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.ORCID 0000-0002-4037-5857
Elrashdy M RedwanDepartment of Biological Science, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-8246-0075

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long COVID, a name often given to the persistent symptoms following acute SARS-CoV-2 infection, poses a multifaceted challenge for health. This review explores the intrinsic relationship between comorbidities and autoimmune responses in shaping the trajectory of long COVID. Autoantibodies have emerged as significant players in COVID-19 pathophysiology, with implications for disease severity and progression. Studies show immune dysregulation persisting months after infection, marked by activated innate immune cells and high cytokine levels. The presence of autoantibodies against various autoantigens suggests their potential as comorbid factors in long COVID. Additionally, the formation of immune complexes may lead to severe disease progression, highlighting the urgency for early detection and intervention. Furthermore, long COVID is highly linked to cardiovascular complications and neurological symptoms, posing challenges in diagnosis and management. Multidisciplinary approaches, including vaccination, tailored rehabilitation, and pharmacological interventions, are used for mitigating long COVID's burden. However, numerous challenges persist, from evolving diagnostic criteria to addressing the psychosocial impact and predicting disease outcomes. Leveraging AI-based applications holds promise in enhancing patient management and improving our understanding of long COVID. As research continues to unfold, unravelling the complexities of long COVID remains paramount for effective intervention and patient care.

Indexed as

ComorbidityCOVID-19Post-Acute COVID-19 SyndromeSARS-CoV-2AutoantibodiesHumansAutoantibodiesautoantibodiescomorbiditiesCOVID-19interplaylong COVIDSARS-CoV-2synergistic effects

Identifiers

PMID39062549
PMCPMC11275036

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.